About us
Towards an optimal clinical data flow...
ClinLine is dedicated to optimize the clinical data flow. Our aim is to efficiently utilize knowledge and innovate technology for effective and efficient use of clinical data in order to reduce both time to market as well as costs for drug and device development.
Improving efficiency for a specific process may not always yield the best results, as it can have unintended consequences at other levels. Optimization is more inclusive and involves all aspects of the process, such as governance, quality, regulatory requirements and making your data FAIR (Findable, Accessible, Interoperable and Reproduceable). Our professionals help you with this process. This includes designing processes and solutions, addressing stakeholder concerns, picturing your future data processes, change impact analysis and actual hands-on data standardization and mapping services.
ClinLine was founded in 2018 by Berber Snoeijer.
With a university degree in Biomedical Sciences and her varied and extensive experience in clinical trial medical writing, data management, data analysis and reporting, she oversees the entire clinical trial data process with all its complexities and is able to link this to trial design and clinical operations.
She owned a Clinical Research Organisation from 2001 to 2008, where she established and managed business processes, created solutions and standards to streamline work, and collaborated with her team on numerous phase 1 to phase 4 trials in various therapeutic areas. Following that, she worked as an R&D manager in a real-world data institute, unlocking the potential of real-world data and designing efficient and reliable tools for this purpose. In 2018, Berber founded ClinLine, which focuses on optimizing the clinical trial process as a whole. Drawing on stakeholder input and requirements, she provides input and designs for data structures, solutions, and process optimization.
For her leadership of Real World Evidence through PHUSE, Berber received PHUSE Influencer Awards for both 2024 and 2025.
